晚期结直肠癌患者行替吉奥或卡培他滨联合奥沙利铂一线治疗的临床疗效对比分析

目的比较晚期结直肠癌患者行替吉奥或卡培他滨联合奥沙利铂一线治疗的临床治疗效果。方法以2013年1月至2015年1月收入我院治疗的晚期结直肠癌患者80例为研究对象,根据治疗方法的不同分为A、B两组,每组40例。A组给予替吉奥联合奥沙利铂治疗,B组给予卡培他滨联合奥沙利铂治疗,观察两组治疗效果与不良反应发生情况。结果 A组与B组治疗总有效率分别为47.5%、42.5%,临床受益率分别为82.5%、80.0%,两组治疗总有效率、临床受益率比较,差异无统计学意义(P0.05);不良反应大多出现在化疗第3周期后,以Ⅰ级、Ⅱ级最为常见,两组患者出现的不良反应主要有胃肠道反应、骨髓抑制、肝功能异常、口腔黏膜炎、手足综合征等,A组患者手足综合征发生率显著低于B组,差异具有统计学意义(P0.05)。结论替吉奥联合奥沙利铂对晚期结直肠癌患者的治疗效果与卡培他滨联合奥沙利铂的疗效基本相同,且引发手足综合征的风险更低,值得临床应用。     

多西他赛联合奥沙利铂及替吉奥对比奥沙利铂联合替吉奥在ⅢC期胃癌术后辅助化疗的临床疗效及不良反应分析

目的比较多西他赛联合奥沙利铂、替吉奥方案与奥沙利铂联合替吉奥方案在ⅢC期胃癌术后辅助化疗的临床疗效及不良反应。方法回顾性分析33例术后分期为ⅢC期的胃癌患者,其中13例术后辅助化疗采用了多西他赛联合奥沙利铂、替吉奥治疗(三药组),20例采用了奥沙利铂联合替吉奥治疗(两药组)。收集两组患者相关资料进行统计分析,比较三药组及两药组的无疾病生存时间(DFS)、总生存时间(OS)及不良反应。结果三药组和两药组的中位DFS分别为22个月和18个月,差异有统计学意义(P=0.018),中位OS分别为27个月和22个月,差异无统计学意义(P=0.066)。两组患者不良反应主要包括骨髓抑制、恶心、呕吐、周围神经毒性及肝肾功能异常等。其中,三药组Ⅲ~Ⅳ度白细胞减少(46.2%vs 10.0%)及血小板降低(30.8%vs 5.0%)的发生率高于两药组,差异有统计学意义(P=0.034,P=0.046);三药组恶心、呕吐发生率也略高于两药组(38.5%vs 20.0%),但差异无统计学意义(P=0.319);其他不良反应包括肝肾功能异常、周围神经毒性等,两组比较,差异均无统计学意义(P>0.05)。结论对于术后分期为ⅢC期的胃癌患者,在奥沙利铂联合替吉奥的标准治疗基础上,加入多西他赛的三药方案,可延长患者的DFS,降低复发转移的风险,且不良反应可耐受,值得扩大样本进一步临床研究。     

黄芪桂枝五物汤对奥沙利铂所致神经及血液毒性的治疗效果观察

目的 探讨黄芪桂枝五物汤加减对奥沙利铂引起的神经毒性及血液毒性的治疗效果.方法 将接受奥沙利铂、亚叶酸钙联合替加氟方案化疗的胃肠道肿瘤患者50例分为治疗组28例、对照组22例.化疗首日治疗组服用黄芪桂枝五物汤加减治疗,对照组服用甲钴铵片.化疗4周期后观察两组神经毒性及血液毒性发生情况.结果 治疗组、对照组神经毒性发生率分别为21.4％、50.0％,治疗组神经毒性发生率低于对照组（P＜0.05）.治疗组白细胞减少、血红蛋白降低、血小板减少的发生率分别为35.7％（10/28）、10.7％ （3/28）、25.0％ （7/28）,对照组分别为40.9％ （9/22）、31.8％（7/22）、36.4％（8/22）,治疗组血红蛋白降低的发生率低于对照组（P＜0.05）.结论 黄芪桂枝五物汤加减能减轻奥沙利铂引起的神经毒性及血液毒性反应.     

奥沙利铂与紫杉醇分别联合5-Fu在胃癌根治术后的应用效果比较

目的比较奥沙利铂(L-OHP)及紫杉醇(PTX)分别联合5-氟尿嘧啶(5-Fu)化疗方案在胃癌根治术后的应用效果及安全性。方法选取2010-06~2013-05该院收治的66例胃癌根治术后患者作为研究对象,按入院顺序编号半随机分为A、B两组各33例。A组采用奥沙利铂联合5-Fu术后辅助化疗方案,B组采用紫杉醇联合5-Fu方案,均随访2年,统计肿瘤复发率、转移率、患者无瘤生存率、总生存率及毒副反应发生率。结果 A组、B组术后1年、2年肿瘤复发、转移率比较差异无统计学意义(P0.05)。A、B组术后1年、2年无瘤生存率、总体生存率比较差异均无统计学意义(P0.05)。A组Ⅲ~Ⅳ度中性粒细胞减少,恶心、呕吐,周围神经毒性、发热、肝功能异常发生率略高于B组,但差异无统计学意义(P0.05)。结论奥沙利铂与紫杉醇分别联合5-Fu在胃癌根治术后辅助化疗中均有确切疗效,患者均可耐受,安全性较高。     

替吉奥单药与联合奥沙利铂治疗进展期胃癌疗效及对生活质量的影响

目的评价替吉奥单药与联合奥沙利铂对胃癌根治术治疗进展期胃癌的临床疗效、生活质量和不良反应。方法 154例行D2根治术,术后组织学证实为Ⅱ期、ⅢA期的进展期胃癌患者,根据患者自己及家属是否愿意行替吉奥单药和替吉奥联合奥沙利铂分为两组,联合组75例,单药组79例。比较两组患者疗效、生活质量及不良反应。结果两组治疗疗效差异有统计学意义(P<0.05)。两组化疗后在白细胞减少、血红蛋白减少、血小板减少、恶心、呕吐、腹泻、肝功能损伤、肾功能损伤、食欲减退等不良反应比较差异无统计学意义(P>0.05)。两组化疗后社会功能、生理功能、躯体疼痛、生理职能、总体健康、活力、情感职能、精神健康、生理评分、心理评分、总评分差异有统计学意义(P<0.01,P<0.001)。结论进展期胃癌行术后替吉奥联合奥沙利铂化疗方案,可以显著提升患者的治疗效果,有效控制不良反应的发生,提高生活质量。     

伊立替康或奥沙利铂联合氟尿嘧啶治疗老年晚期胃癌的临床疗效及安全性研究

目的探讨伊立替康或奥沙利铂联合氟尿嘧啶一线治疗老年晚期胃癌的临床疗效及安全性。方法收取2011年1月至2015年6月间陕西省人民医院收治的老年晚期胃癌患者82例作为研究对象,采用随机数字表法将其分为伊立替康组及奥沙利铂组各41例,分别给予伊立替康联合氟尿嘧啶及奥沙利铂联合氟尿嘧啶治疗。对两组患者近期疗效、远期疗效、不良反应以及生活质量恢复情况进行观察与比较。结果伊立替康组患者RR和DCR分别为41.46%和75.61%,奥沙利铂组患者RR和DCR分别为31.71%和73.17%,两组相较差异无统计学意义(P0.05)。两组患者TTP无统计学差异(P0.05)。伊立替康组患者在白细胞减少及腹泻等方面发生率高于奥沙利铂组患者,周围神经病变低于奥沙利铂组患者,差异均有统计学意义(P0.05)。伊立替康组患者生活质量恢复总有效率为73.17%,奥沙利铂组为68.29%,两组相较无显著差异(P0.05)。结论两种化疗方案一线治疗老年晚期胃癌临床疗效相当,奥沙利铂联合氟尿嘧啶安全性较高,值得临床推广应用。     

奥沙利铂联合甲酰四氢叶酸钙、氟尿嘧啶和联合希罗达两周方案治疗晚期胃癌的研究

目的 观察奥沙利铂联合甲酰四氢叶酸钙和氟尿嘧啶(FOLFOX4)与联合希罗达(XELOX)两周方案在晚期胃癌中的疗效和不良反应.方法晚期胃癌患者52例,FOLFOX4化疗22例,XELOX两周方案化疗30例,均于化疗2个疗程后评价疗效,并于1个月后确认,对比其疗效和毒副反应.结果 FOLFOX4方案组总有效率为40.9%,XELOX方案组总有效率为46.7%,两组间比较无明显差异.不良反应主要为外周神经毒性、骨髓抑制、恶心呕吐和腹泻,多为Ⅰ、Ⅱ度,XELOX组手足综合征发生率明显高于FOLFOX4组,但都为Ⅰ、Ⅱ度.结论FOLFOX4和XELOX两周方案治疗晚期胃癌均有较好的疗效,毒副反应均可以耐受.     

替吉奥胶囊联合奥沙利铂加与不加紫杉醇治疗晚期胃癌的疗效对比

目的对比替吉奥胶囊联合奥沙利铂加与不加紫杉醇治疗晚期胃癌的临床疗效。方法选取2012年5月—2013年5月我院收治的晚期胃癌患者88例,将其随机分为对照组和观察组,各44例。对照组给予替吉奥胶囊+奥沙利铂化疗方案,观察组给予替吉奥胶囊+奥沙利铂+紫杉醇化疗方案,比较两组患者的临床疗效和毒副作用。结果两组总有效率比较,差异无统计学意义(P0.05);观察组临床受益率为88.6%(39/44),高于对照组的70.5%(31/44)(P0.05);观察组周围神经毒性发生率、脱发发生率低于对照组(P0.01)。结论替吉奥胶囊联合奥沙利铂加紫杉醇较不加紫杉醇治疗晚期胃癌疗效好,且毒副作用发生率低,安全性较高。     

替吉奥联合奥沙利铂一线治疗晚期胃癌疗效观察

目的探讨替吉奥联合奥沙利铂治疗晚期胃癌的临床疗效。方法 58例晚期胃癌患者随机分为治疗组28例和对照组30例,治疗组采用奥沙利铂联合替吉奥治疗,对照组采用奥沙利铂联合5-FU治疗;21 d为1个周期,2个周期后评价疗效。结果治疗组总有效率为46.4%,对照组为43.3%,两组疗效无统计学差异（P〉0.05）。发生恶心呕吐不良反应治疗组Ⅰ～Ⅱ度4例,对照组Ⅰ～Ⅲ度16例;发生口腔黏膜炎不良反应治疗组Ⅰ度1例,对照组Ⅰ～Ⅱ度8例。治疗组恶心呕吐及口腔黏膜炎发生率高于对照组（P均〈0.05）。结论奥沙利铂联合替吉奥治疗晚期胃癌疗效好,不良反应发生率低,更适合年老体弱患者。     

FOLFOX、XELOX、SOX 方案用于局部进展期胃腺癌的疗效及安全性比较

目的：比较FOLFOX、XELOX、SOX方案用于局部进展期胃腺癌患者新辅助化疗的临床疗效及安全性。方法将106例局部进展期胃腺癌患者随机分为A、B、C三组,分别给予FOLFOX（奥沙利铂＋甲酰四氢叶酸钙＋5-氟尿嘧啶）、XELOX（奥沙利铂＋卡培他滨）、SOX（奥沙利铂＋替吉奥胶囊）进行化疗,化疗2个周期后复查胃镜及64排螺旋CT,比较其临床疗效及不良反应。结果 A、B、C组的总有效率分别为51．43％、62．86％、66．67％,B、C组的总有效率均高于A组（P均＜0．05）,B、C组比较无统计学差异（P＞0．05）。 B、C组药物不良反应发生率较A组降低,特别是Ⅲ度以上不良反应发生率更低（P均＜0．05）,B、C组比较无统计学差异（P＞0．05）。结论 FOL-FOX、XELOX、SOX方案用于局部进展期胃腺癌患者新辅助化疗均有效、安全,XELOX、SOX方案的疗效更佳,安全性更高。     

FOLFOX4方案治疗晚期胃癌40例临床观察

目的观察FOLFOX4方案治疗晚期胃癌的临床疗效及毒副反应。方法40例晚期胃癌患者，给予FOLFOX4方案化疗。即：奥沙利铂（L-OHP）85mg／m^2。静脉点滴，2h，dl；亚叶酸钙（LV）200mg／m^2，静脉点滴，2h，d1，d2；氟尿嘧啶（5-FU）400mg／m^2静脉推注，后600mg／m^2微泵持续静脉滴注22h，d1，d2；每2周重复，4周为1周期。均治疗2周期以上，按WHO标准评价客观疗效和毒副反应。结果全组40例均可评价疗效，其中完全缓解（CR）3例，部分缓解（PR）17例，稳定（SD）13例，进展（PD）7例，总有效率（CR＋PR）50．0％。中位肿瘤进展时间（m）5．7个月，中位生存时间（MST）为9．8个月。毒副反应主要是骨髓抑制，胃肠道反应及外周神经毒性。白细胞下降发生率为75．0％。主要为Ⅰ／Ⅱ度反应，恶心呕吐发生率62．5％，腹泻30．0％。口腔粘膜炎22．5％。L—OHP引起的可逆性周围神经毒性发生率为45．0％，表现为肢端感觉异常，遇冷加重，但患者一般都能耐受。结论FOLFOX4方案治疗国人晚期胃癌的近期疗效较好，毒副反应可以耐受，值得进一步研究应用。     

以多西他赛为主二联与三联疗法对老年低分化胃癌的疗效对比分析

目的对比以多西他赛为主二联和三联疗法对老年低分化胃癌的临床效果。方法将60例老年低分化胃癌患者随机分成三联化疗组和二联化疗组,每组30例。二联化疗组给予多西他赛联合奥沙利铂方案化疗,三联化疗组给予多西他赛联合奥沙利铂、替吉奥方案化疗。对两组近期疗效、KPS评分、肿瘤进展时间(TTP)、生存时间(OS)及不良反应进行比较。结果二联化疗组客观缓解率、临床获益率为36.7%、63.3%,三联化疗组客观缓解率、临床获益率为33.3%、70.0%,差异无统计学意义(P0.05);治疗后,二联化疗组KPS评分为(71.5±6.6)分,显著性低于三联化疗组的(79.5±7.9)分,差异有统计学意义(P0.05);二联化疗组TTP为8.5个月,三联化疗组TTP为8.7个月,差异无统计学意义(P0.05);二联化疗组OS为13.4个月,三联化疗组OS为15.1个月,差异无统计学意义(P0.05);二联化疗组不良反应(白细胞降低、贫血、乏力)率显著低于三联化疗组,差异有统计学意义(P0.05)。结论相比于多西他赛为主三联疗法,多西他赛为主二联疗法对对老年低分化胃癌效果同样显著,且不良反应较少,适合老年人使用。     

Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma

AIM:To evaluate the effects and safety of combination chemotherapy with oxaliplatin (L-OHP) and S-1 (SOX regimen) in older patients with advanced gastric cardiac adenocarcinoma (GCA). METHODS: Seventy patients with advanced GCA were classified according to age into an older group (≥ 75 years) and a control group (< 75 years). The SOX regimen was administered to the two groups as follows: S-1 (40 mg/m2 po bid) on days 1 to 14 followed by a 7-d off period, plus L-OHP (65 mg/m2 iv) for 2 h on days 1 and 8 of a...     

FOLFOX、XELOX方案联合腹腔镜治疗进展期胃癌的研究

背景:单一的手术、放疗、化疗对进展期胃癌疗效均欠佳,近年来多学科协作诊治模式(MDT)越来越受重视。目的:探讨术前FOLFOX、XELOX化疗方案联合腹腔镜治疗进展期胃癌的疗效。方法:纳入2009年2月~2013年2月新疆生产建设兵团第一师医院和新疆生产建设兵团医院收治的进展期胃癌患者,给予FOLFOX或XELOX化疗方案联合腹腔镜胃癌D2根治术,对两种治疗方案的疗效进行比较分析。结果:共54例患者纳入研究,FOLFOX组29例,XELOX组25例。化疗后临床完全缓解(CR)7例,部分缓解(PR)23例,疾病稳定(SD)15例,疾病进展(PD)9例,总有效率(RR)为55.6%(30/54),FOLFOX、XELOX组间疗效差异无统计学意义(P0.05)。XELOX组患者恶心、呕吐、骨髓抑制以及腹泻的发生率显著低于FOLFOX组(P0.05),口腔黏膜炎、手足综合征的发生率显著高于FOLFOX组(P0.05)。45例患者经腹腔镜切除肿瘤,9例患者行腹腔镜探查术,未切除肿瘤,FOLFOX、XELOX组间手术切除率差异无统计学意义(P0.05)。FOLFOX、XELOX组术后病理分期均较治疗前显著降低(P0.05)。结论:术前FOLFOX、XELOX方案联合腹腔镜治疗进展期胃癌疗效相似,具有良好的有效性和安全性。     

Oral Xeloda plus bi-platinu two-way combined chemotherapy in treatment of advanced gastrointestinal malignancies

AIM: To compare the effect, adverse events, cost-effectiveness and dose intensity (DI) of oral Xeloda vs calcium folinate (CF)/5-FU combination chemotherapy in patients with advanced gastrointestinal malignancies, both combined with bi-platinu two-way chemotherapy. METHODS: A total of 131 patients were enrolled and randomly selected to receive either oral Xeloda (X group) or CF/5-FU (control group). Oral Xeloda 1 000 mg/m2 was administered twice daily from d 1 to 14 in X group, while CF 200 mg/m2 was taken as a 2-h intravenous infusion followed by 5-FU 600 mg/m2 intravenously for 4-6 h on d 1-5 in control group. Cisplatin and oxaliplatin were administered in the same way to both the groups: cisplatin 60-80 mg/m2 by hyperthermic intraperitoneal administration, and oxaliplatin 130 mg/m2 intravenously for 2 h on d 1. All the drugs were recycled every 21 d, with at least two cycles. Pyridoxine 50 mg was given t.i.d. orally for prophylaxis of the hand-foot syndrome (HFS). Then the effect, adverse events, cost-effectiveness and DI of the two groups were evaluated. RESULTS: Hundred and fourteen cases (87.0%) finished more than two chemotherapy cycles. The overall response rate of them was 52.5% (X group) and 42.4% (control group) respectively. Tumor progression time (TTP) was 7.35 mo vs 5.95 mo, and 1-year survival rate was 53.1% vs 44.5%. There was a remarkable statistical significance of TTP and 1-year survival between the two groups. The main Xeloda-related adverse events were myelosuppression, gastrointestinal toxicity, neurotoxicity and HFS, which were mild and well tolerable. Therefore, no patients withdrew from the study due to side effects before two chemotherapy cycles were finished. Both groups finished pre-arranged DI and the relative DI was nearly 1.0. The average cost for 1 patient in one cycle was Y9 137.35 (X group) and Y8 961.72 (control group), or US $1100.89 in X group and $1 079.73 in control group. To add 1% to the response rate costs ￥161.44 vs ￥210.37 respectively (US $19.45 vs $25.35). One-month prolongation of TTP costs ￥1 243.18 vs ￥1506.17 (US $149.78 vs $181.47). Escalation of 1% of 1-year survival costs ￥172.74 vs ￥201.64 (US $20.75 vs $24.29). CONCLUSION: Oral Xeloda combined with bi-platinu two-way combination chemotherapy is efficient and tolerable for patients with advanced gastrointestinal malignancies; meanwhile the expenditure is similar to that of CF/5-FU combined with bi-platinu chemotherapy, and will be cheaper if we are concerned about the increase of the response rate, TTP or 1-year-survival rate pharmacoeconomically.     

Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study

The treatment efficacy of advanced breast cancer is still not promising. This study aimed to compare the efficacy and safety of docetaxel/S-1 (DS1) versus docetaxel/capecitabine (DX) as the first-line treatment for advanced breast cancer.From June 2008 to June 2013, 22 patients with advanced breast cancer were treated with the DS1 regimen. Another 26 age- and disease status-matched patients treated with the DX regimen served as controls. The 2 groups were compared in terms of time to progression (TTP), objective response rate, disease control rate, clinical benefit rate, and safety profiles.Median TTP did not differ significantly between the DS1 group and the DX group (9.04 vs 10.94 months, P = 0.473). There were no significant differences in objective response rate, disease control rate, and clinical benefit rate between the 2 groups. Both the DS1 and the DX regimens showed good tolerability. The 2 regimens showed no significant difference in adverse events except degree III hand-foot syndrome (DS1 0 vs DX 23.1%, P = 0.025).For the first-line treatment of advanced breast cancer, the DS1 and the DX regimens showed similar efficacy and safety. The DS1 regimen had less severe hand-foot syndrome than the DX regimen.     

Hand-foot syndrome associated with uracil/tegafur and docetaxel in a patient with lung cancer]

A 30-year-old woman given a diagnosis of stage IV lung adenocarcinoma, was admitted to our hospital because of chest pain due to pleuritis carcinomatosa. She had taken uracil/tegafur (UFT) 600mg orally every day from September 2004. Uracil/tegafur was stopped in December 10, 2005, and docetaxel (taxotere) 50mg/m2 was given in December 12, 2005. Seven days after treatment with docetaxel she developed erythema and spontaneous pain of the palms and fingers of both hands and soles of both feet. The erythema increased gradually, and 10 days after docetaxel infusion she could not walk due to severe pain. After improvement of the painful erythema, desquamation of fingers of both hands and the soles of both feet occurred. She was diagnosed with hand-foot syndrome. Although the same amount of docetaxel was given later, hand-foot syndrome was not seen. Therefore it was suggested that both uracil/tegafur and docetaxel induced hand-foot syndrome. Fluoropyrimidines and taxanes have been reported as common anti-cancer drugs that lead to hand-foot syndrome. Since these drugs play a crucial role in lung cancer treatment, we need to pay attention to hand-foot syndrome. A sufficient off-drug period is required in the sequential usage of fluoropyrimidines and taxanes.     

Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer

AIM： To investigate the efficacy and side effects of the combined therapy of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer （ESCC） and the survival of the patients. METHODS： Sixty-four patients （median age of 63 years） with histological or cytological confirmation of ESCC received oxaliplatin 120 mg/m^2 intravenously on day 1 and capecitabine 1000 mg/m^2 orally twice daily on days 1 to 14 in a 21-d treatment cycle as palliative chemotherapy. Each patient received at least two cycles of treatment. The efficacy, side effects and patient survival were evaluated. RESULTS： The partial response （PR） rate was 43.8% （28/64）. Stable disease （SD） rate was 47.9% （26/64）, and disease progression rate was 15.6% （10/64）. The clinical benefit rate （PR ＋ SD） was 84.4%. The main toxicities were leukopenia （50.0%）, nausea and vomiting （51.6%）, diarrhea （50.0%）, stomatitis （39.1%）, polyneuropathy （37.5%） and hand-foot syndrome （37.5%）. No grade 4 event in the entire cohort was found. The median progression-free survival was 4 mo, median overall survival was 10 mo （95% CI： 8.3-11.7 mo）, and the 1- and 2-year survival rates were 38.1% and 8.2%, respectively. High Karnofsky index, single metastatic lesion and response to the regimen indicated respectively good prognosis. CONCLUSION： Oxaliplatin plus capecitabine regimen is effective and tolerable in metastatic ESCC patients. The regimen has improved the survival moderately and merits further studies.     

紫杉醇与卡培他滨联合治疗进展期胃癌38例的临床疗效和安全性

目的评价紫杉醇与卡培他滨联合治疗进展期胃癌的临床疗效及安全性。方法随机抽取徐州医学院附属医院2012年11月-2014年4月收治的进展期胃癌患者76例作为研究对象,将其分为观察组和对照组,分别给予紫杉醇联合卡培他滨治疗和紫杉醇、顺铂和5-FU联合治疗,在治疗期间对其临床疗效和毒副反应进行评估分析。结果两组患者的有效率相比,差异无统计学意义(P0.05),而骨髓抑制和手足综合征的毒副反应相比,差异有统计学意义(P0.05)。结论紫杉醇联合卡培他滨联合治疗进展期胃癌安全有效,患者能够耐受毒副反应,值得临床推广使用。     

恩度联合FOLFOX4方案对中晚期胃癌的临床疗效及血清肿瘤抗原变化水平分析

目的探讨重组人血管内皮抑制素注射液恩度联合FOLFOX4方案对中晚期胃癌的临床疗效及安全性。方法将湖北医药学院附属十堰市太和医院收治的74例中晚期胃癌患者随机分为观察组和对照组,对照组采用FOLFOX4方案,观察组采用FOLFOX4联合恩度方案;对比两组患者临床疗效、血清肿瘤标志物变化水平及不良反应发生情况。结果观察组有效率显著高于对照组(59.46%vs 32.43%),两组相比差异具有统计学意义(χ2=13.913,P0.05);与对照组相比,观察组血清CEA、CA50、CA125、CA153、CA199水平显著降低(P0.05);两组相比,各不良反应发生率差异无统计学意义(P0.05)。结论恩度联合FOLFOX4方案对中晚期胃癌的临床有效,不良反应均可耐受,是一种安全有效的治疗方案,值得临床推广。